BC022651 Inhibitors
Chemical inhibitors of BC022651 encompass a range of compounds that target various kinases and signaling pathways crucial for the protein's function. Staurosporine, a potent kinase inhibitor, can inhibit BC022651 by preventing phosphorylation, a post-translational modification required for BC022651's activation and function. Similarly, wortmannin and LY294002, both inhibitors of phosphoinositide 3-kinases (PI3K), can halt the PI3K pathway, thus impeding BC022651's signaling cascade. The inhibition of PI3K by these chemicals would lead to a decrease in BC022651 activity, as it relies on PI3K signaling for its function. Rapamycin directly inhibits the mTOR pathway, which is intricately linked with the PI3K/Akt pathway, and its inhibition can diminish BC022651's action by curtailing downstream signaling events that are pivotal for BC022651's role within the cell.
Moreover, triciribine targets the Akt pathway, reducing BC022651 activity by directly inhibiting the pathway upon which BC022651's function is contingent. PD98059 and U0126, both MEK inhibitors, can block the MAPK/ERK pathway, which, if integral to BC022651's mechanism, would result in its functional inhibition. SP600125 and SB203580 inhibit the JNK and p38 MAPK pathways, respectively, and their inhibitory effects would extend to BC022651 if it operates as a downstream component within these pathways. Lestaurtinib and AG490, targeting JAK kinases and the JAK/STAT pathway, would suppress BC022651's activity if it is part of the JAK/STAT signaling cascade. Lastly, ZM447439, an Aurora kinase inhibitor, can inhibit BC022651 by disrupting cell cycle processes or other Aurora kinase-dependent functions that BC022651 might regulate. Each of these chemicals executes its inhibitory effect by disrupting specific pathways that are essential for BC022651's functional role within the cell, thereby achieving targeted inhibition of the protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit BC022651 by blocking the phosphorylation events that are necessary for the protein's activation and subsequent signal transduction. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). Given that BC022651 is a part of the PI3K pathway, inhibition of PI3K by Wortmannin would lead to a decrease in BC022651 downstream signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K. It would inhibit BC022651 by preventing the initiation of the PI3K pathway, which is necessary for BC022651's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR), a downstream effector in the PI3K/AKT pathway. This would reduce the activity of BC022651 by inhibiting downstream signaling events that BC022651 participates in. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the Akt pathway. Since BC022651's function is dependent on this pathway, its inhibition by Triciribine would lead to decreased BC022651 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. If BC022651 activity is dependent on this pathway, PD98059 would lead to functional inhibition of BC022651. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also an inhibitor of MEK. It would inhibit BC022651 by blocking the MAPK/ERK pathway, which is essential for the functional activity of BC022651. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. By inhibiting JNK, SP600125 can lead to the functional inhibition of BC022651 if it is a downstream effector of this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. Inhibition of p38 MAPK would result in functional inhibition of BC022651 if BC022651's activity is contingent upon signaling through this kinase. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $270.00 $320.00 $600.00 | 3 | |
Lestaurtinib inhibits Janus kinases (JAKs), which are associated with the JAK/STAT pathway. Inhibition of this pathway would lead to functional inhibition of BC022651 if it operates downstream of JAK signaling. | ||||||